1-6 of 6
L. Lai
Close
Sort by
Journal Articles

Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA

Manu Thomas Kalathottukaren, Libin Abraham, Piyushkumar R. Kapopara, Benjamin F. L. Lai, Rajesh A. Shenoi, Federico I. Rosell, Edward M. Conway, Edward L. G. Pryzdial, James H. Morrissey, Charles A. Haynes, Jayachandran N. Kizhakkedathu
Journal: Blood
Blood (2017) 129 (10): 1368–1379.
https://doi.org/10.1182/blood-2016-10-747915
Published: 2017
Includes: Supplemental data
Journal Articles

A Novel Polymer Based Antidote for Reversing the Anticoagulation Effect of Clinically Used Heparins,

Rajesh A Shenoi, PhD, Benjamin F L Lai, MSc, Dirk Lange, PhD, Donald E Brooks, PhD, Ben Chew, MD, Cedric John Carter, MD, Jayachandran N Kizhakkedathu, PhD
Journal: Blood
Blood (2011) 118 (21): 3359.
https://doi.org/10.1182/blood.V118.21.3359.3359
Published: 2011
Journal Articles

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

Paul Richardson, S. Lonial, A. Jakubowiak, A. Krishnan, J. Wolf, J. Densmore, S. Singhal, I. Ghobrial, J. Stephenson, J. Mehta, K. Colson, D. Francis, T. Kendall, N. Obadike, K. Sullivan, J. Martin, T. Hideshima, L. Lai, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson, K. Anderson
Journal: Blood
Blood (2007) 110 (11): 1164.
https://doi.org/10.1182/blood.V110.11.1164.1164
Published: 2007
Journal Articles

A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).

Paul Richardson, S. Lonial, A. Jakubowiak, J. Wolf, A. Krishnan, J. Densmore, S. Singhal, I. Ghobrial, L. Schwartzberg, K. Colson, J. Harris, T. Kendall, B. Martineau, N. Obadike, K. Sullivan, S. Pearson, T. Hideshima, L. Lai, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson, K.C. Anderson
Journal: Blood
Blood (2006) 108 (11): 3582.
https://doi.org/10.1182/blood.V108.11.3582.3582
Published: 2006
Journal Articles

A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly High Rates of Baseline Peripheral Neuropathy.

Paul Richardson, A. Chanan-Khan, R. Schlossman, N. Munshi, P. Wen, H. Briemberg, D. Kuter, A. Oaklander, S. Lonial, H. Hassoun, D. Doss, L. Lunde, S. Hayes, M. McKenney, K. Hande, L. Lai, A. Freeman, K. Dinand, C. McAlister, D. Warren, D. Collins, D. Esseltine, A. Amato, K. Anderson
Journal: Blood
Blood (2005) 106 (11): 2548.
https://doi.org/10.1182/blood.V106.11.2548.2548
Published: 2005
Journal Articles

Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses

J. Pinilla-Ibarz, K. Cathcart, T. Korontsvit, S. Soignet, M. Bocchia, J. Caggiano, L. Lai, J. Jimenez, J. Kolitz, D. A. Scheinberg
Journal: Blood
Blood (2000) 95 (5): 1781–1787.
https://doi.org/10.1182/blood.V95.5.1781.005k46_1781_1787
Published: 2000